Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Indiana
Clinical trial register · United States · industry-sponsored

Clinical Trials in Indiana, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company49 AstraZeneca41 AbbVie41 Janssen Research & Development, LLC39 Merck Sharp & Dohme LLC32
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Indiana

1124 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Missouri
2027-11-23
Not yet open
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
NCT07703436Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma
DrugSafusidenib
Nuvation Bio Inc.
Phase 2
40
California, Connecticut, Florida, Indiana, New Jersey, New York, Ohio
2027-03
Not yet open
Home-Based Lower-Extremity Heat Therapy for Walking Function in Peripheral Artery Disease
NCT07653243PAD, PAD - Peripheral Arterial Disease
Aquilo Sports, LLC
Not applicable
40
Indiana
2027-01-01
Not yet open
Sacrum Pressure Injury Prevention Study Using ALLEVYN◊ Complete Care in Adults at Risk of Developing Hospital-acquired Pressure Injuries in Critical Care Units
NCT07849387Pressure Ulcers (Hospital-acquired Pressure Injuries)
Smith & Nephew, Inc.
Not applicable
330
Colorado, Georgia, Indiana
2026-10-30
Not yet open
Knee Cartilage Repair Registry
NCT07786207Knee Injuries, Joint Surface Knee Lesions
Smith & Nephew, Inc.
Observational
1,000
Colorado, District of Columbia, Indiana, Kentucky, Oklahoma, Pennsylvania
2026-09-30
Recruiting
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
NCT07668414Overweight, Obesity
DrugsZenagamtide·Semaglutide
Novo Nordisk A/S
Phase 3
650
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana, Missouri
2026-09-22
Recruiting
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
NCT07819435Androgenetic Alopecia
Pelage Pharmaceuticals, Inc.
Phase 2/3
600
Arkansas, California, Florida, Georgia, Indiana, Louisiana, Minnesota, Missouri
2026-09-21
Recruiting
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
NCT07540988Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
466
Alabama, California, Connecticut, Florida, Indiana, Kansas, Michigan, Minnesota
2026-09-17
Recruiting
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
NCT07828860Hidradenitis Suppurativa (HS)
DrugSoquelitinib
Corvus Pharmaceuticals, Inc.
Phase 1
25
Indiana, Kentucky, Massachusetts, New York, North Dakota, Ohio, Pennsylvania, Tennessee
2026-09-17
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264Secondary Immune Deficiency
DrugHizentra
CSL Behring
Phase 3
63
California, Colorado, Florida, Indiana, Maryland, New Jersey, New York, North Carolina
2026-09-15
Recruiting
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
NCT07619118Hypercholesterolaemia
DrugsRosuvastatin 1·Rosuvastatin 2
AstraZeneca
Phase 3
200
Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland, North Carolina
2026-09-10
Recruiting
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924Cutaneous Lichen Planus
DrugGIA632
Novartis Pharmaceuticals
Phase 2
259
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2026-09-10
Recruiting
Device for Treating Generalized Anxiety
NCT07819773Generalized Anxiety Disorder (GAD)
BTL Industries Ltd.
Not applicable
40
Colorado, Illinois, Indiana
2026-09-09
Not yet open
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
NCT07598825Autoimmune Hepatitis, AIH
DrugInebilizumab
Amgen
Phase 3
180
Arkansas, California, Indiana, Texas
2026-09-07
Not yet open
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
NCT06965504Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
Abiomed Inc.
Not applicable
250
Florida, Indiana, Minnesota, Missouri, New Jersey, North Carolina, Pennsylvania, Tennessee
2026-09-01
By invitation
OsteoFlo HydroFiber Ambispective Evaluation
NCT07784673OsteoFlo HydroFiber
SurGenTec LLC
Observational
100
Illinois, Indiana
2026-09-01
Recruiting
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07743671Hereditary Hemorrhagic Telangiectasia
DrugEngasertib
Vaderis Therapeutics AG
Phase 3
240
Illinois, Indiana, Minnesota, Missouri
2026-09
Not yet open
A Trial to Assess the Safety and Effectiveness of an Anatomic Total Shoulder System
NCT07812324Shoulder Arthroplasty, Total Shoulder Arthroplasty
Medacta USA
Not applicable
286
Arizona, Florida, Indiana, Maryland, New Hampshire, New York, Oregon, Pennsylvania
2026-09
Not yet open
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
NCT07766005Hidradenitis Suppurativa (HS)
DrugsSPY072·Bimekizumab
Spyre Therapeutics, Inc.
Phase 2
150
California, Indiana, Kentucky, Louisiana, Massachusetts, New York, South Carolina, Texas
2026-09
Not yet open
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 3
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2026-09
Not yet open
Clinical Assessment of the Safety and Efficacy of Flaus Electric Flosser on Plaque and Gingivitis Compared to a Manual Toothbrush
NCT07805148Gingivitis, Gingival Bleeding, Dental Plaque
Flaus, Inc
Not applicable
80
Indiana
2026-08-31
Recruiting
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
NCT07720271Overweight, Obesity
DrugZenagamtide
Novo Nordisk A/S
Phase 3
950
Alabama, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana
2026-08-31
Recruiting
Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)
NCT07766655Smoking Cessation
DrugsDextromethorphan-bupropion·Bupropion
Axsome Therapeutics, Inc.
Phase 3
705
Arkansas, California, Florida, Georgia, Illinois, Indiana, Missouri, New York
2026-08-27
Recruiting
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
NCT07783802Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension
DrugClazakizumab
Eli Lilly and Company
Phase 2
120
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2026-08-27
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
NCT07729462Preventive Treatment of Migraine
DrugRimegepant
Pfizer
Phase 3
400
Arizona, California, Florida, Indiana, Massachusetts, Michigan, Missouri, Nebraska
2026-08-26
Recruiting
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
NCT07795814Heart Failure With Preserved Ejection Fraction
Edgewise Therapeutics, Inc.
Phase 2
90
Alabama, California, Illinois, Indiana, Kentucky, Louisiana, Maryland, Michigan
2026-08-25
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
DrugZenagamtide
Novo Nordisk A/S
Phase 3
1,778
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2026-08-24
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
NCT07772492Severe Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
300
California, Florida, Idaho, Indiana, Nebraska, Ohio, Texas
2026-08-24
Recruiting
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
NCT07700056Chronic Pruritus of Unknown Origin
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Florida, Georgia, Indiana, New York, Ohio, South Carolina, Texas
2026-08-24
Recruiting
Safety and Efficacy of Flaus Electric Flosser on Plaque and Gingivitis Compared to a Manual Toothbrush
NCT07779564Gingivitis, Gingival Bleeding, Dental Plaque
Flaus, Inc
Not applicable
80
Indiana
2026-08-18
Recruiting
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)
NCT07585968Ventricular Tachycardia
Medtronic Cardiac Ablation Solutions
Not applicable
260
Indiana, New York, North Carolina, Ohio, Texas
2026-08-17
Recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
NCT07702032Left-sided Colorectal Cancer
DrugsPetosemtamab·MFOLFOX6·Folfiri·Cetuximab
Genmab
Phase 3
960
Georgia, Indiana, Missouri, Washington
2026-08-11
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411Atrial Fibrillation (AF)
DrugsCenvacibart·Apixaban
Regeneron Pharmaceuticals
Phase 3
15,364
Alabama, Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland
2026-08-10
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly and Company
Phase 2
606
Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan
2026-08-07
Recruiting
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
NCT07612878COPD (Chronic Obstructive Pulmonary Disease)
DrugDupilumab
Sanofi
Observational
350
Indiana, North Carolina, Texas
2026-08-06
Recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07282613Diabetes Mellitus, Type 2
DrugCagriSema
Novo Nordisk A/S
Phase 3
80
Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, New York
2026-08-04
Recruiting
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
NCT07745504Overweight, Obesity
DrugCagrilintide
Novo Nordisk A/S
Phase 3
285
Georgia, Hawaii, Illinois, Indiana, Kentucky, North Carolina, South Carolina, Virginia
2026-08-04
Recruiting
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
NCT07723248Metastatic Castration Resistant Prostate Cancer
DrugsRinzimetostat·Xtandi·Taxotere·Darolutamide
ORIC Pharmaceuticals
Phase 3
600
Florida, Indiana, Michigan, North Carolina, Ohio, South Carolina, Tennessee, Texas
2026-08-03
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Pirtobrutinib
Nurix Therapeutics, Inc.
Phase 3
620
Georgia, Indiana, Tennessee, Texas, Virginia
2026-08-03
Recruiting
Study of Resmetirom in Children and Adolescents With MASH
NCT07763015MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugResmetirom
Madrigal Pharmaceuticals, Inc.
Phase 2
61
Indiana
2026-08-01
Not yet open
TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)
NCT07684313Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Tricuspid Valve Disease
Edwards Lifesciences
Observational
75
Indiana
2026-08
Not yet open
A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.
NCT06458907Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
P+F Products + Features USA Inc.
Not applicable
780
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2026-08
Recruiting
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
NCT07733765Alopecia Areata
DrugRitlecitinib
Pfizer
Phase 3
336
California, Florida, Illinois, Indiana, Iowa, Maryland, Michigan, North Carolina
2026-07-30
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795Colorectal Cancer
DrugsVS-7375·Panitumumab·MFOLFOX6·Cetuximab
Verastem, Inc.
Phase 2
150
California, Florida, Indiana, Michigan, Missouri, New Jersey, New York, Tennessee
2026-07-28
Recruiting
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07601425Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
DrugATV-1601
Atavistik Bio, Inc
Phase 1/2
100
Arizona, Georgia, Indiana, Massachusetts, Minnesota, Utah
2026-07-27
Recruiting
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
NCT07734649Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
DrugHMPV vaccine
Sanofi
Phase 1/2
2,400
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-07-22
Recruiting
Study of GS-0415 and How It Works in People With HIV
NCT07719491HIV -1 Infection
Gilead Sciences
Phase 1
112
California, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Nevada, New Jersey
2026-07-22
Recruiting
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
NCT07656415Sickle Cell Disease
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
159
Indiana, Michigan, Mississippi
2026-07-21
Recruiting
A Study to Investigate the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival Health
NCT07704905Dental Plaque, Gingivitis
HALEON
Not applicable
110
Indiana
2026-07-13
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
710
Arkansas, California, Florida, Illinois, Indiana, Nebraska, New York, North Carolina
2026-07-10
Recruiting
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
NCT07318610Peripheral Artery Disease (PAD)
DrugsAmrecibart·Cenvacibart·Rivaroxaban
Regeneron Pharmaceuticals
Phase 3
7,050
Alabama, Arizona, Arkansas, California, Florida, Indiana, Louisiana, North Carolina
2026-07-10
Recruiting
Intalight Reference Database Protocol for VG200D
NCT07751484The Focus of This Study is to Collect OCT Data on Normal Eyes
Intalight, Inc
Observational
350
California, Illinois, Indiana
2026-07-08
Recruiting
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
NCT07602842Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
InduPro, Inc.
Phase 1/2
132
California, Florida, Indiana, New York, Texas
2026-07-08
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
DrugsElecoglipron·Dapagliflozin
AstraZeneca
Phase 3
2,000
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2026-07-06
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241Small Cell Lung Cancer
DrugsABBV-706·Amrubicin·Lurbinectedin·Topotecan
AbbVie
Phase 3
531
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-07-02
Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
NCT07536269Congenital Adrenal Hyperplasia
DrugCrinecerfont
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Recruiting
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
NCT07684820Chronic Obstructive Pulmonary Disease (COPD)
Expedition Therapeutics, Inc
Phase 2
600
Arizona, California, Colorado, Florida, Georgia, Indiana, Kansas, Minnesota
2026-06-30
Recruiting
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07643766Atopic Dermatitis
DrugENV-294
Enveda Therapeutics
Phase 2
200
California, Florida, Indiana, Texas
2026-06-29
Recruiting
A Study of MZE782 in Adults With PKU
NCT07694440Phenylketonuria (PKU)
Maze Therapeutics
Phase 2
38
California, Indiana, Kentucky, Pennsylvania, Tennessee
2026-06-23
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
NCT07668388Diabetes Mellitus, Type 2
DrugsUBT251·Semaglutide
Novo Nordisk A/S
Phase 2
300
Alabama, California, Florida, Indiana, Kansas, Maryland, North Carolina, North Dakota
2026-06-22
Recruiting
A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction
NCT07657182Peripheral Nerve Injury, Peripheral Nerve Discontinuity, Mixed Peripheral Nerve Injury, Motor Peripheral Nerve Injury
Axogen Corporation
Phase 4
178
Indiana
2026-06-12
Recruiting
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
NCT07309445Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Observational
150
Alabama, Arkansas, California, Colorado, Florida, Illinois, Indiana, Michigan
2026-06-12
Recruiting
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
NCT07595549Obesity, Overweight and/or Obesity, Overweight
DrugBerobenatide
Pfizer
Phase 3
954
California, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan, Nebraska
2026-06-10
Active, closed
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021Obesity
DrugsNNC0662-0419·Semaglutide
Novo Nordisk A/S
Phase 2
233
Alabama, California, Florida, Illinois, Indiana, Kentucky, Maryland, Missouri
2026-06-09
Recruiting
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
NCT07448038Atherosclerosis
Genentech, Inc.
Phase 2
162
California, Connecticut, Florida, Indiana, Michigan, Minnesota, Missouri, Nebraska
2026-06-05
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881Focal Seizure, Epilepsy, Focal Epilepsy
DrugRAP-219
Rapport Therapeutics Inc.
Phase 3
333
California, Florida, Georgia, Idaho, Indiana, Maryland, New Jersey, New York
2026-06-05
Recruiting
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy
NCT07675135EDS, Cataplexy, Fatigue, Narcolepsy
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
258
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-06-04
Recruiting
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
NCT07489885Psoriasis
DrugD-2570
InventisBio Co., Ltd
Phase 2
75
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kentucky
2026-06-03
Recruiting
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
NCT07586618Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
Allterum Therapeutics, Inc
Phase 1
24
Colorado, Indiana, New York, Ohio, Pennsylvania, Texas
2026-06-01
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Not yet open
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
NCT04457076Contraception, Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,525
California, Colorado, Georgia, Hawaii, Indiana, Minnesota, Missouri, Nevada
2026-06-01
Recruiting
Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.
NCT07270380Osteomyelitis
Biocomposites Ltd
Not applicable
139
California, Indiana, Maryland, New Jersey
2026-06
Recruiting
Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
NCT07477691Phenylketonuria
DrugsPegvaliase·Methotrexate
BioMarin Pharmaceutical
Phase 4
12
California, Colorado, Florida, Illinois, Indiana, Minnesota, New York, Oregon
2026-05-29
Recruiting
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
NCT07609914Acute Treatment of Migraine
DrugRimegepant
Pfizer
Phase 4
400
California, Florida, Indiana, Massachusetts, Michigan, Minnesota, Mississippi, Nevada
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Connecticut, Florida, Georgia, Indiana, Maryland, New Jersey, New York, Ohio
2026-05-27
Recruiting
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
NCT07614776Neovascular Age-related Macular Degeneration, nAMD
Amgen
Phase 3
304
California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts
2026-05-27
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587Multiple Myeloma (MM)
Shanghai Henlius Biotech
Phase 1
258
Arkansas, Florida, Indiana, Louisiana, Texas, Washington
2026-05-25
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582Alzheimer Disease, Dementia, Plaque, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 3
550
Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa
2026-05-22
Recruiting
Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency
NCT07636590Limbal Stem Cell Deficiency
Claris Biotherapeutics, Inc.
Observational
500
Indiana, Kansas, Kentucky, Minnesota, Oregon, Tennessee, Texas
2026-05-22
Recruiting
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
NCT07633470Alzheimer Disease
Alpha Cognition, Inc
Phase 4
150
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-05-20
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
Recruiting
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
NCT06948214Growth Hormone Deficiency (GHD)
DrugLUM-201
Lumos Pharma
Phase 3
150
Alabama, California, Colorado, District of Columbia, Florida, Indiana, Iowa, Louisiana
2026-05-20
Recruiting
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650Type 2 Diabetes Mellitus, T2DM
DrugHM15275
Hanmi Pharmaceutical Company Limited
Phase 2
180
Arizona, Florida, Georgia, Indiana, Missouri, Nebraska, Nevada, North Carolina
2026-05-18
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
California, Florida, Georgia, Indiana, Maryland, Missouri, New York, North Carolina
2026-05-14
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Recruiting
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
NCT07572006Hematologic Neoplasms
Janssen Research & Development, LLC
Phase 1
360
Indiana, Michigan, New Jersey, New York, Tennessee, Texas
2026-05-13
Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098Breast Neoplasms
DrugsImlunestrant·Goserelin·Tamoxifen
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky
2026-05-13
Recruiting
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
NCT07503886Dry Eye Disease (DED)
DrugDFL24498
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
NCT07582432Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
DrugGamunex-C
Grifols Biologicals, LLC
Phase 3
49
Florida, Indiana, Maine, Ohio, Washington
2026-05-11
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156Urothelial Cancer, Urinary Bladder Neoplasms
DrugsMitomycin C·Enfortumab Vedotin·Fluorouracil·Keytruda
Astellas Pharma Global Development, Inc.
Phase 3
390
California, Colorado, Delaware, Illinois, Indiana, Missouri, Ohio, Oregon
2026-05-11
Recruiting
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT07214532Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Natera, Inc.
Not applicable
725
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana
2026-05-08
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Arizona, California, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota
2026-05-06
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
DrugXNW27011
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Alabama, California, Florida, Georgia, Indiana, Michigan, New Jersey, New York
2026-05-04
Recruiting
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
NCT07610395Rhinovirus Infection
Altesa Biosciences, Inc.
Phase 2
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-05-01
Not yet open
Optimization for Toric Contact Lenses
NCT07557030Astigmatism, Ametropia
CooperVision International Limited (CVIL)
Not applicable
45
Indiana
2026-05
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2026-05
Recruiting
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
NCT07521475Type 2 Diabetes Mellitus
Insulet Corporation
Not applicable
350
California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Massachusetts
2026-04-30
Recruiting
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
NCT07446322Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
DrugsPelareorep·Folfiri·Avastin·Bevacizumab
Oncolytics Biotech
Phase 2
60
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Michigan
2026-04-30
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772Irritable Bowel Syndrome, Constipation
DrugBrenipatide
Eli Lilly and Company
Phase 2
342
Arizona, California, Florida, Illinois, Indiana, Kentucky, New York, Ohio
2026-04-29
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NCT07416604Hemophilia A
DrugEmicizumab
Hoffmann-La Roche
Phase 3
360
California, Colorado, Florida, Indiana, Iowa, Washington
2026-04-27
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Arizona, California, Colorado, Florida, Illinois, Indiana, New York, Oregon
2026-04-23
Active, closed
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
NCT07503210Obesity
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
606
Alabama, California, Florida, Illinois, Indiana, North Carolina, Pennsylvania, Rhode Island
2026-04-21
Recruiting
Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque/Low Gingivitis and High Plaque/High Gingivitis
NCT07614490Gingivitis, Plaque
Colgate Palmolive
Phase 4
100
Indiana
2026-04-20
Recruiting
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
NCT07241234Phenylketonuria
Agios Pharmaceuticals, Inc.
Phase 1
20
Indiana, Pennsylvania, Texas
2026-04-17
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
245
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-04-13
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
California, Illinois, Indiana, Maine, Tennessee, Texas
2026-04-08
Active, closed
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
NCT07497880Obesity, Overweight
Kailera
Phase 2
306
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2026-04-06
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
NCT07430956Atrial Fibrillation (AF)
DrugsAmrecibart·Cenvacibart
Regeneron Pharmaceuticals
Phase 3
2,628
Alabama, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2026-04-03
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Indiana, Louisiana, Michigan, North Carolina, Texas
2026-04-01
Active, closed
Registry Analysis of Deceased Donor Kidney Transplant Outcomes
NCT07530991Normothermic Machine Perfusion (NMP) of Deceased Donor Kidneys
Chris Jaynes
Observational
3,500
Indiana
2026-04-01
Not yet open
Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs)
NCT07412626Congestive Heart Failure Chronic, Low Ejection Fraction
Robert Pickett
Not applicable
135
Indiana, Tennessee
2026-04-01
Recruiting
Zimmer Biomet-RibFix Titan
NCT07485829Rib Fracture, Rib Fracture Multiple
Zimmer Biomet
Observational
54
Indiana
2026-03-31
Recruiting
A Clinical Study to Assess the Effectiveness of Use of Three Experimental Denture Adhesives Compared to Using No-Adhesive
NCT07496164Denture Retention
HALEON
Not applicable
60
Indiana
2026-03-30
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, Michigan
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2026-03-26
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
DrugsCasdatifan·Pumitamig·Cabozantinib·Yervoy
Bristol-Myers Squibb
Phase 1/2
474
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Maryland, Michigan
2026-03-26
Recruiting
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
NCT07216235Primary Biliary Cholangitis
DrugSaroglitazar Magnesium
Zydus Therapeutics Inc.
Phase 3
386
Georgia, Indiana, Texas
2026-03-24
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019Secondary Progressive Multiple Sclerosis
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
990
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-03-23
Recruiting
Testing Conversational Agents as a Digital Companion
NCT07533331Autism
Friendi.fi Corporation
Not applicable
38
Indiana, Kentucky
2026-03-21
Recruiting
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
NCT07532603Lichen Planopilaris
DrugBrepocitinib
Priovant Therapeutics, Inc.
Phase 2/3
342
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2026-03-19
Recruiting
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
NCT07538583Netherton Syndrome
Quoin Pharmaceuticals
Phase 2/3
16
California, Connecticut, Indiana, Massachusetts, Texas
2026-03-19
Recruiting
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
NCT07366086Osteogenesis Imperfecta
Amgen
Phase 3
71
Indiana
2026-03-18
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
DrugsMarlotamig·Ubamatamab·Sarilumab
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana
2026-03-18
Recruiting
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367Adenovirus Infections
SymBio Pharmaceuticals
Phase 3
180
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2026-03-17
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky
2026-03-16
Recruiting
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
NCT07500090Idiopathic Hypersomnia
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
248
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Michigan
2026-03-16
Recruiting
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
NCT07475806Muscle-invasive Bladder Cancer
DrugsEnfortumab Vedotin·Pembrolizumab
Astellas Pharma Global Development, Inc.
Phase 2
240
Arkansas, Illinois, Indiana, Michigan, New Jersey, New York, Pennsylvania, South Carolina
2026-03-12
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-12
Recruiting
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
NCT07457918Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
600
Florida, Indiana, Ohio, Texas
2026-03-11
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
DrugGIA632
Novartis Pharmaceuticals
Phase 2
210
Alabama, California, Florida, Indiana, Michigan, Nebraska, Nevada, New York
2026-03-09
Recruiting
TOUCH® CMC 1 New Enrollment US Study
NCT07405983Osteoarthritis Thumb, Thumb Carpometacarpal Joint Osteoarthritis
Keri Medical SA
Observational
163
Colorado, Indiana, North Carolina, Texas
2026-03-04
Active, closed
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
NCT07458269Obesity
DrugRibupatide
Kailera
Phase 2
264
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-03-04
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Alabama, Arizona, California, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2026-03-03
Recruiting
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
NCT07453602Atopic Dermatitis (AD), Eczema
Arcutis Biotherapeutics, Inc.
Phase 1
125
Florida, Indiana, New Jersey, Texas, Utah
2026-03-02
Recruiting
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07306559Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim
Phase 1
187
California, Indiana, Texas
2026-02-27
Recruiting
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
NCT07432958Parkinson Disease
Appello Pharmaceuticals, Inc.
Phase 2
150
Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky
2026-02-25
Recruiting
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
NCT07339423Obesity
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
1,150
Florida, Georgia, Illinois, Indiana, Missouri, New York, North Carolina, Pennsylvania
2026-02-24
Recruiting
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
NCT07568730Neurotrophic Keratitis
TearSolutions, Inc.
Phase 2
54
Florida, Indiana, Massachusetts, Minnesota, Missouri, New York
2026-02-19
Recruiting
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
NCT07356323Arthroplasty Replacement, Knee, Arthroplasty Total Hip Replacement
Solventum US LLC
Not applicable
179
Indiana, Utah
2026-02-19
Active, closed
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07435428Moderate to Severe Glabellar Lines
DrugCorabotase
Ipsen
Phase 3
1,300
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-02-18
Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
DrugsCemsidomide·Dexamethasone
C4 Therapeutics, Inc.
Phase 2
100
Alabama, Arizona, California, Florida, Georgia, Indiana, Iowa, Michigan
2026-02-18
Recruiting
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
NCT07362017Moderate-to-severe Chronic Plaque Psoriasis
DrugPonesimod
Vanda Pharmaceuticals
Phase 3
300
Arizona, California, Florida, Indiana, New Hampshire, New York, North Carolina, Texas
2026-02-17
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsSetidegrasib·Levofolinate·Liposomal Irinotecan·Fluorouracil
Astellas Pharma Global Development, Inc.
Phase 3
614
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Indiana, Kentucky
2026-02-17
Recruiting
A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions
NCT06894329Pancreatic Cystic Lesions
Amplified Sciences Inc
Observational
50
Indiana, Massachusetts, New Jersey
2026-02-17
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558Ovarian Neoplasms, Ovarian Cancer
DrugsMvasi·Sacituzumab tirumotecan·Avastin·Bevacizumab
Merck Sharp & Dohme LLC
Phase 3
900
Alabama, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maine
2026-02-16
Active, closed
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
240
California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana
2026-02-16
Recruiting
Aspiration Thrombectomy Using the Symphony or Prodigy System
NCT07350499Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
Imperative Care, Inc.
Observational
750
Alabama, Florida, Illinois, Indiana, Michigan, New York, Ohio, Virginia
2026-02-13
Recruiting
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283Opioid Use Disorder
DrugsBuprenorphine·Brenipatide
Eli Lilly and Company
Phase 2
465
Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maryland
2026-02-13
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer
Phase 2/3
1,156
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2026-02-11
Active, closed
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
NCT07425392Pneumococcal Vaccines
Drugs31-valent pneumococcal conjugate vaccine·Prevnar 20
Vaxcyte, Inc.
Phase 3
752
Arizona, Connecticut, Florida, Georgia, Indiana, Kansas, Louisiana, Maryland
2026-02-09
Active, closed
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2026-02-09
Recruiting
A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury
NCT07455136Traumatic Brain Injury
Hoffmann-La Roche
Observational
2,000
California, Indiana, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee
2026-02-09
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts
2026-02-09
Recruiting
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
NCT07280013Multiple Myeloma (MM)
DrugsCemsidomide·Elranatamab
C4 Therapeutics, Inc.
Phase 1
60
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-02-06
Recruiting
A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System
NCT07118501Post Traumatic Arthritis, Osteoarthritis, Total Ankle Replacement, Total Ankle Prosthesis
Stryker Trauma and Extremities
Observational
200
Illinois, Indiana, Kentucky, Oregon, South Carolina
2026-02-06
Recruiting
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
NCT07340320Type II Diabetes Mellitus
DrugCX11
Corxel Pharmaceuticals
Phase 2
240
Alabama, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts
2026-02-06
Recruiting
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
NCT07224321Type 1 Diabetes Mellitus
Mannkind Corporation
Phase 2
100
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Oklahoma, Texas
2026-02-04
Recruiting
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH
Phase 2/3
300
California, Indiana, Mississippi, Missouri, New York, Ohio, Oregon, Vermont
2026-02-02
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Alabama, California, Colorado, Connecticut, Florida, Indiana, Kansas, Michigan
2026-02-02
Recruiting
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07259317Adenocarcinoma, Carcinoma, Pancreatic Ductal
DrugsRelacorilant·Nab-paclitaxel·Gemcitabine
Corcept Therapeutics
Phase 2
80
Arizona, California, Florida, Georgia, Indiana, Kansas, Michigan, Minnesota
2026-01-27
By invitation
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
NCT07286006Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
372
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2026-01-26
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184944Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
751
Colorado, Florida, Illinois, Indiana, Louisiana, Missouri, New York, North Carolina
2026-01-22
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Arizona, California, Florida, Indiana, Louisiana, Maryland, Michigan, Minnesota
2026-01-22
Active, closed
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860Dermatitis, Atopic
Janssen Research & Development, LLC
Phase 2
189
California, Florida, Illinois, Indiana, Michigan, North Dakota, Oregon, Pennsylvania
2026-01-20
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07185009Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
751
Arizona, California, Colorado, Florida, Indiana, Louisiana, Michigan, Missouri
2026-01-16
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Arkansas, California, Florida, Georgia, Illinois, Indiana, New Mexico, North Carolina
2026-01-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
NCT07355062CKD, Metabolic Acidosis
Renibus Therapeutics, Inc.
Phase 3
150
California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana
2026-01-13
Active, closed
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
NCT07365826Pneumococcal Vaccines
Drug31-valent pneumococcal conjugate vaccine
Vaxcyte, Inc.
Phase 3
1,390
Arizona, Colorado, Florida, Indiana, Kansas, Kentucky, Michigan, Nebraska
2026-01-12
Recruiting
A Study of Buntanetap in Participants With PD
NCT07284784Parkinson's Disease (PD), Deep Brain Stimulation
DrugBuntanetap/posiphen
Annovis Bio Inc.
Phase 2/3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2026-01-09
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
460
California, Florida, Georgia, Idaho, Indiana, Kansas, Louisiana, Maryland
2026-01-08
Recruiting
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07095452Multiple Myeloma
DrugsEtentamig·Daratumumab·Lenalidomide·Dexamethasone
AbbVie
Phase 2/3
680
Arizona, California, Colorado, Georgia, Indiana, Minnesota, New York, North Carolina
2026-01-08
By invitation
MDR Vivacit-E Elevated Study
NCT07150221Osteoarthritis (OA) of the Hip, Avascular Necrosis of Bone of Hip, Protrusio Acetabuli, Traumatic Arthropathy-Hip
Zimmer Biomet
Observational
52
Indiana
2026-01-07
By invitation
Lead Evaluation for Defibrillation and Reliability Post Approval Study
NCT07005232Tachyarrhythmia
Medtronic
Observational
2,000
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2026-01-07
Recruiting
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
NCT07187973Sickle Cell Disease
DrugDISC-3405
Disc Medicine, Inc
Phase 1
24
Alabama, California, Georgia, Illinois, Indiana, New York, North Carolina, Ohio
2026-01-06
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Arizona, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-01-06
Recruiting
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
NCT07217587Myasthenia Gravis
DrugsEfgartigimod·Nipocalimab
Janssen Research & Development, LLC
Phase 3
115
California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts
2026-01-05
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Pumitamig·Folfox·Bevacizumab
Bristol-Myers Squibb
Phase 2/3
990
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2025-12-31
Recruiting
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
NCT07392255Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Phase 1/2
75
Indiana, Nevada, Texas, Wisconsin
2025-12-30
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569Hidradenitis Suppurativa
Sanofi
Phase 2
144
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky
2025-12-29
Active, closed
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660Atopic Dermatitis
DrugGalvokimig
UCB Biopharma SRL
Phase 2
165
California, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Nebraska
2025-12-29
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin
AstraZeneca
Phase 3
1,100
Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky
2025-12-29
Recruiting
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
NCT07110454Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Observational
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Minnesota
2025-12-23
Recruiting
Diagnosing Epilepsy To EffeCT Change
NCT07110337Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Not applicable
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2025-12-23
Recruiting
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
NCT07254806Degenerative Disc Disease
DiscGenics, Inc.
Phase 3
162
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Indiana, Kentucky
2025-12-23
Recruiting
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07298395Atopic Dermatitis (AD)
DrugENV-294
Enveda Therapeutics
Phase 2
105
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-12-22
Recruiting
Children's Viewing Behavior
NCT07229365Myopia, Myopia Progression, Juvenile Myopia
SightGlass Vision, Inc.
Not applicable
20
Indiana
2025-12-22
Recruiting
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
NCT07265947Low Grade Upper Tract Urothelial Carcinoma
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
230
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2025-12-22
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
NCT07246590Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
Florida, Indiana, Maryland, Tennessee, Texas
2025-12-17
Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Observational
175
Indiana, New York, Ohio, Oregon, Texas
2025-12-17
Recruiting
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT06956690Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
Hummingbird Bioscience
Phase 1/2
180
California, Indiana, Michigan, Texas
2025-12-17
Recruiting
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07288138Metabolic Dysfunction-associated Steatohepatitis
DrugECC4703
Eccogene
Phase 2
160
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Maryland
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-12-15
Recruiting
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07062588Osteogenesis Imperfecta (OI)
DrugAGA2115
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study
NCT06604884Intracranial Aneurysm
Medtronic Neurovascular Clinical Affairs
Observational
118
Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri, South Carolina
2025-12-12
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07217717Pancreatic Ductal Adenocarcinoma (PDAC)
Drug[18F]FAPI-74 PET/CT
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-12-11
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer, c-MET
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Arkansas, California, Florida, Indiana, Minnesota, Nebraska, New Hampshire, New Jersey
2025-12-10
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945Chronic Kidney Disease
DrugDapagliflozin
Boehringer Ingelheim
Phase 3
120
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2025-12-09
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland
2025-12-08
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Active, closed
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
160
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, New York
2025-12-03
Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
NCT07260877Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus)
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Recruiting
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281Atopic Dermatitis
DrugAbrocitinib
Pfizer
Phase 3
500
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-12-02
Active, closed
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
NCT07284654Pneumococcal Vaccines
Drugs31-valent pneumococcal conjugate vaccine·Capvaxive·Prevnar 20
Vaxcyte, Inc.
Phase 3
4,049
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2025-12-01
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
NCT07144852Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
260
Arizona, California, Colorado, Florida, Idaho, Illinois, Indiana, Minnesota
2025-11-29
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York
2025-11-28
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Alabama, Arizona, California, Florida, Indiana, Michigan, Minnesota, Nebraska
2025-11-27
By invitation
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
NCT07450664Prader-Willi Syndrome
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-11-26
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab
AbbVie
Phase 2
180
Connecticut, Florida, Indiana, Kentucky, Massachusetts, Michigan, Missouri, Ohio
2025-11-25
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531Type 1 Diabetes
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
By invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
1,370
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-11-25
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958Acute Myeloid Leukemias
DrugRevumenib
Syndax Pharmaceuticals
Phase 3
468
Arizona, California, Indiana, Louisiana, Rhode Island, Texas
2025-11-25
Active, closed
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015Atopic Dermatitis
DrugKT-621
Kymera Therapeutics, Inc.
Phase 2
200
Alabama, Arkansas, California, Florida, Illinois, Indiana, Michigan, New York
2025-11-24
Recruiting
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
NCT07213778Symptomatic Venous Thromboembolism (VTE)
DrugsCenvacibart·Acetylsalicylic acid
Regeneron Pharmaceuticals
Phase 3
2,000
California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-11-24
Active, closed
Taldefgrobep Alfa in Adults With Overweight and Obesity
NCT07281495Obesity, Overweight
DrugTaldefgrobep alfa
Biohaven Therapeutics Ltd.
Phase 2
150
California, Florida, Illinois, Indiana, Louisiana, Missouri, North Carolina, North Dakota
2025-11-24
Recruiting
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT06890338Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
DrugsMIRV·Mirvetuximab Soravtansine·Bevacizumab·Carboplatin
AbbVie
Phase 2
140
Alabama, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana
2025-11-21
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
NCT07144345Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
160
California, Florida, Illinois, Indiana, Minnesota, Missouri, Oregon, South Carolina
2025-11-19
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
Drug[18F]FAPI-74 PET/CT
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-11-14
Active, closed
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390Hidradenitis Suppurativa
DrugRitlecitinib
Pfizer
Phase 2
128
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-11-13
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 2
160
Alabama, California, District of Columbia, Florida, Georgia, Indiana, Iowa, Kentucky
2025-11-12
Active, closed
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
NCT07216482Hyperlipidemia
DrugsEnlicitide·Rosuvastatin
Merck Sharp & Dohme LLC
Phase 3
996
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2025-11-11
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts
2025-11-10
Recruiting
Assessing Connected-Health, Pressure-Monitoring Technology for Improving Compression Therapy in Venous Leg Ulcer Treatment
NCT07152717Venous Leg Ulcers (VLUs)
Feeltect Limited
Not applicable
40
Indiana
2025-11-06
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
DrugSurabgene Lomparvovec
AbbVie
Phase 3
561
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2025-11-05
Active, closed
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642Obesity, Overweight
DrugCagrilintide
Novo Nordisk A/S
Phase 3
300
California, Colorado, Florida, Illinois, Indiana, Missouri, North Carolina, Virginia
2025-11-05
Active, closed
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759Overweight, Obesity, Type 2 Diabetes
DrugCagrilintide
Novo Nordisk A/S
Phase 3
330
Alabama, Arizona, California, Florida, Hawaii, Indiana, Nevada, New York
2025-11-05
Recruiting
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 1
24
Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-11-03
Active, closed
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644Hidradenitis Suppurativa (HS)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2/3
210
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Michigan
2025-11-03
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2025-10-31
Recruiting
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
NCT07142356Uncontrolled Hypertension
Retension Pharmaceuticals. Inc.
Phase 2
280
Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Louisiana
2025-10-31
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
DrugGSK3862995B
GlaxoSmithKline
Phase 2
363
Alabama, Arizona, California, Colorado, Florida, Indiana, Louisiana, Maryland
2025-10-30
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822Breast Cancer
DrugDato-DXd
AstraZeneca
Phase 3
100
Florida, Indiana, Nebraska, New York, Texas, Washington
2025-10-30
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-10-28
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07211178Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
Tempus AI
Observational
900
Alabama, California, Florida, Illinois, Indiana, Michigan, Missouri, Nevada
2025-10-27
Recruiting
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
NCT07220564Haemophilia A
Novo Nordisk A/S
Phase 1
30
Colorado, Indiana, Iowa, Pennsylvania
2025-10-23
Recruiting
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
NCT07027514Non Small Cell Lung Cancer
DrugsTolododekin alfa·Cetrelimab
Ankyra Therapeutics, Inc
Phase 1
60
Florida, Illinois, Indiana, Michigan, Minnesota, New York, North Carolina, Pennsylvania
2025-10-22
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Active, closed
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
NCT07074977Chronic Pruritus of Unknown Origin
DrugNemolizumab
Galderma R&D
Phase 2
50
Alabama, Arizona, California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-10-20
Recruiting
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194Coronary Artery Disease
Orchestra BioMed, Inc
Not applicable
740
Florida, Indiana, Kansas, Maryland, Michigan, New York, North Carolina, Ohio
2025-10-20
Recruiting
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
NCT07175428Atrial Fibrillation (AF)
DrugsAmrecibart·Cenvacibart·Apixaban
Regeneron Pharmaceuticals
Phase 2
1,200
Alabama, California, Florida, Georgia, Indiana, Louisiana, Maryland, Massachusetts
2025-10-20
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
DrugBexobrutideg
Nurix Therapeutics, Inc.
Phase 2
100
Arizona, California, Colorado, Florida, Indiana, Iowa, Maryland, Michigan
2025-10-15
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
DrugsDurvalumab·Carboplatin
IDEAYA Biosciences
Phase 1/2
262
Colorado, Florida, Indiana, Michigan, New York, Pennsylvania, Tennessee, Texas
2025-10-14
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
675
Alabama, Connecticut, Florida, Georgia, Indiana, Maine, New Jersey, New York
2025-10-08
Recruiting
The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study
NCT07142304Chemotherapy Induced Peripheral Neuropathy (CIPN)
Luminate Medical, Inc.
Not applicable
142
California, Connecticut, Florida, Hawaii, Illinois, Indiana, Minnesota, New Jersey
2025-10-03
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia
NCT07841470Keratoconus, Corneal Ectasia
Price Vision Group
Phase 2/3
500
Indiana
2025-10-01
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Recruiting
EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures
NCT07020520Ureteral Stricture
Urotronic Inc.
Not applicable
60
California, Florida, Indiana, New York, Texas, Utah
2025-10-01
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
710
Florida, Indiana, Louisiana, North Carolina, Ohio, South Dakota, Texas
2025-09-30
Recruiting
Clinical Course Of Disease In Participants With FA-CM
NCT06865482Friedreich Ataxia, Cardiomyopathy
Lexeo Therapeutics
Observational
65
California, Florida, Indiana, Massachusetts, Minnesota, Missouri, Ohio, Oregon
2025-09-30
Recruiting
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
NCT06776783Respiratory Distress Syndrome, Pre-term Infants
Aerogen Pharma Limited
Phase 3
520
Arkansas, California, Florida, Indiana, New Jersey, New York, Texas, Virginia
2025-09-24
Active, closed
In-situ Clinical Trial Assessing Ability to Detect and Monitor Active Caries and Their Remineralization
NCT07100626Dental Caries
Incisive Technologies Pty Ltd
Not applicable
12
Indiana
2025-09-24
Recruiting
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
NCT06941870Factor VIII Deficiency
DrugEfanesoctocog alfa
Sanofi
Phase 4
35
California, Indiana, Iowa, Ohio
2025-09-23
Recruiting
GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
NCT06827990Aortic Dissection
W.L.Gore & Associates
Not applicable
112
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-09-22
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
DrugLunsekimig
Sanofi
Phase 3
942
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2025-09-16
Recruiting
AMEND TS Early Feasibility Study
NCT06951672Symptomatic Functional MR 3 or Greater
Valcare Medical Ltd.
Not applicable
15
Arizona, California, Georgia, Indiana, New York, Oregon, Tennessee, Texas
2025-09-11
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
DrugsErdafitinib·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-09-10
Recruiting
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
140
California, Florida, Indiana, Maryland, Michigan, Nebraska, New Mexico, New York
2025-09-10
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
NCT06689839Aortic Stenosis Treated With TAVI, Aortic Diseases
EnCompass Technologies, Inc.
Not applicable
500
Florida, Indiana, Michigan, Missouri, New York, Ohio, Virginia
2025-09-09
Recruiting
Post-Approval Study of the Neuspera Sacral Neuromodulation System
NCT07144813Urinary Urgency Incontinence
Neuspera Medical, Inc.
Not applicable
116
California, Florida, Indiana, Kansas, Kentucky, Louisiana, Michigan, Minnesota
2025-09-03
Active, closed
A Study Evaluating TRIV-509 in Atopic Dermatitis
NCT07167758Atopic Dermatitis
Triveni Bio
Phase 2
95
California, Florida, Indiana, Pennsylvania, Texas, Washington
2025-08-26
Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843Primary Membranous Nephropathy
DrugBudoprutug
Climb Bio, Inc.
Phase 2
45
Colorado, Florida, Georgia, Indiana, Massachusetts, New York, Texas
2025-08-25
Recruiting
PSMA PET Combined With MRI for the Detection of PCa
NCT07052214PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
DrugIlluccix
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
338
California, Florida, Illinois, Indiana, Louisiana, Missouri, New York, Pennsylvania
2025-08-18
Recruiting
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
NCT07049328Alopecia Areata(AA)
HCW Biologics
Phase 1
30
Florida, Indiana, Ohio
2025-08-16
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
150
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-08-14
Recruiting
Abbott Cephea Mitral Valve Disease Registry
NCT07069673Mitral Regurgitation, Mitral Stenosis, Mitral Valve Disease, Mitral Valve (MV) Regurgitation
Abbott Medical Devices
Observational
1,000
Alabama, Arizona, California, Georgia, Illinois, Indiana, Kansas, Minnesota
2025-08-13
Recruiting
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07160179Geographic Atrophy, Age-Related Macular Degeneration
DrugSyfovre
AbbVie
Phase 1/2
66
Indiana, Nevada, Texas
2025-08-13
Recruiting
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865Sickle Cell Disease
DrugRilzabrutinib
Sanofi
Phase 3
192
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-08-12
Recruiting
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
NCT06988618Prurigo Nodularis
Galderma R&D
Observational
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-08-11
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-08-11
Active, closed
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199Diabetes Mellitus, Type 1
DrugsInsulin aspart·Insulin glargine·Insulin icodec
Novo Nordisk A/S
Phase 3
877
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-08-11
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-08-06
Recruiting
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
NCT06825559Cholestatic Liver Disease
DrugSaroglitazar Magnesium
Zydus Therapeutics Inc.
Phase 1
6
Indiana
2025-08-05
Recruiting
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
NCT07089888Tophaceous Gout
DrugsDotinurad·Allopurinol
Crystalys Therapeutics
Phase 3
250
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-04
Recruiting
Scalable Intervention for Stress Management
NCT07127575Stress, Diaphragmatic Breathing
Livotion, LLC
Not applicable
60
Indiana
2025-08-01
Recruiting
A Study of Dotinurad Versus Allopurinol in Participants With Gout
NCT07089875Gout
DrugsDotinurad·Allopurinol
Crystalys Therapeutics
Phase 3
500
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-01
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maine
2025-08-01
Not yet open
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
NCT06531031Bloodstream Infection, Sepsis, Septic Shock
Microbio Co Ltd
Observational
1,500
Indiana, Maryland, New Mexico, Tennessee, Texas
2025-08
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
208
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-07-31
Recruiting
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
NCT07024693Fuchs Endothelial Corneal Dystrophy, Fuchs
Design Therapeutics, Inc.
Phase 2
70
Indiana, Michigan
2025-07-30
Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT07144137Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Observational
75
California, Illinois, Indiana, Nevada, North Carolina, Pennsylvania, Texas, Wisconsin
2025-07-30
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399Macular Edema Secondary to Inflammation
DrugKSI-101
Kodiak Sciences Inc
Phase 3
600
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Connecticut, Florida, Georgia, Illinois, Indiana, Michigan, Missouri, South Dakota
2025-07-30
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
California, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey, New York
2025-07-28
Recruiting
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
NCT07010159Pericarditis, Pericarditis Acute, Recurrent Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
Arizona, California, Colorado, District of Columbia, Georgia, Illinois, Indiana, Kansas
2025-07-25
Recruiting
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268Eczema
DrugAbrocitinib
Pfizer
Phase 3
150
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-07-24
Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
NCT06911632Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Tempus AI
Not applicable
900
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky
2025-07-23
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759Neovascular Age-Related Macular Degeneration (nAMD)
DrugsEYLEA (aflibercept)·4D-150 IVT
4D Molecular Therapeutics
Phase 3
480
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-07-22
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan, Mississippi
2025-07-21
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080Macular Edema Secondary to Inflammation
DrugKSI-101
Kodiak Sciences Inc
Phase 3
300
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-16
Active, closed
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
NCT07105488Atopic Dermatitis (AD)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Louisiana, Massachusetts, Michigan
2025-07-15
Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605Atopic Dermatitis
Galderma R&D
Observational
1,000
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-07-14
Active, closed
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Arizona, California, Colorado, Florida, Georgia, Indiana, Louisiana, Massachusetts
2025-07-14
Recruiting
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
NCT06999733Neurotrophic Keratitis
Krystal Biotech, Inc.
Phase 1/2
60
California, Indiana, Minnesota, Missouri, New Jersey, North Dakota, Pennsylvania
2025-07-07
Active, closed
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118Prostatic Cancer, Castration-Resistant
DrugsLuxdegalutamide·Lu-PSMA
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-07-02
Active, closed
Stone and Laser Therapies Post-Market Study (SALT)
NCT06982235Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary
Boston Scientific Corporation
Observational
238
Arizona, Florida, Indiana, North Carolina
2025-06-30
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Arizona, California, Colorado, Florida, Georgia, Indiana, Louisiana, Maine
2025-06-30
Recruiting
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
NCT07001800Moderate Aortic Valve Stenosis
Kardigan, Inc.
Phase 2/3
1,276
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-27
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
90
Alabama, Arkansas, California, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-06-27
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07007637Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
835
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-27
Recruiting
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
NCT06935591Atrial Fibrillation (AF)
Vektor Medical
Not applicable
423
Arkansas, Florida, Georgia, Indiana, Kentucky, New York, Ohio, Pennsylvania
2025-06-27
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
California, Colorado, Florida, Indiana, Kansas, Maryland, Massachusetts, Minnesota
2025-06-26
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099Crohn's Disease, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
290
Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana
2025-06-26
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
350
Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana
2025-06-26
Recruiting
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
NCT06464926Nausea, Vomiting
Enterra Medical, Inc.
Not applicable
148
Arizona, California, Florida, Illinois, Indiana, Kentucky, New Jersey, Ohio
2025-06-23
Active, closed
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 3
580
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-06-23
Recruiting
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
NCT07215390Geographic Atrophy Secondary to Age-related Macular Degeneration
DrugPegcetacoplan
Apellis Pharmaceuticals, Inc.
Phase 2
240
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-23
Recruiting
4-day Plaque Accumulation Model Evaluating Compound Containing Gum
NCT06984744Dental Plaque Accumulation
Lactea Therapeutics, LLC
Not applicable
32
Indiana
2025-06-23
Recruiting
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta
W.L.Gore & Associates
Observational
1,500
Arizona, California, District of Columbia, Florida, Georgia, Indiana, Maryland, Massachusetts
2025-06-19
Recruiting
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257Heart Failure
DrugPF-07328948
Pfizer
Phase 2
620
California, Florida, Illinois, Indiana, Maryland, Nebraska, Ohio, Texas
2025-06-19
Recruiting
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
NCT06608823Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
JenaValve Technology, Inc.
Not applicable
1,016
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-06-18
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
DrugsRisankizumab·Vedolizumab
AbbVie
Phase 3
573
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-17
Active, closed
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
NCT07009860Alcohol-associated Liver Disease
DrugPemvidutide
Altimmune, Inc.
Phase 2
121
Arizona, Arkansas, California, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-06-16
Active, closed
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792Atopic Dermatitis
DrugLebrikizumab
Eli Lilly and Company
Phase 4
233
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-16
Recruiting
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
NCT06789913PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation
DrugRLY-2608
Relay Therapeutics, Inc.
Phase 2
277
Arizona, Arkansas, California, Colorado, Georgia, Indiana, Iowa, Maryland
2025-06-13
Active, closed
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235Hidradenitis Suppurativa
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
149
Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Massachusetts
2025-06-09
By invitation
Virtuos Bone Graft in Lumbar Fusion
NCT06686017Degenerative Disc Disease
Orthofix Inc.
Observational
150
Indiana, Michigan, Montana, North Carolina, South Carolina, Texas, Virginia
2025-06-05
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839Macular Edema
Boehringer Ingelheim
Phase 2
300
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-06-05
Active, closed
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667Obesity
DrugCagriSema
Novo Nordisk A/S
Phase 3
609
California, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri
2025-06-03
Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
DrugsTNG462·RMC-9805·Gemcitabine-nab-paclitaxel·MFOLFIRINOX
Tango Therapeutics, Inc.
Phase 1/2
183
Arizona, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa, Massachusetts
2025-05-31
Active, closed
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706Atopic Dermatitis, Atopic, Dermatitis, AD
Aclaris Therapeutics, Inc.
Phase 2
110
Arizona, Arkansas, California, Florida, Georgia, Idaho, Indiana, Kentucky
2025-05-30
Active, closed
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
NCT07023731KRAS G12D Mutation, Advanced Solid Cancer
Arvinas Inc.
Phase 1/2
76
Arizona, Connecticut, Florida, Indiana, Michigan, New York, North Carolina, Ohio
2025-05-29
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
3,103
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-05-28
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Alabama, Arkansas, California, Florida, Idaho, Illinois, Indiana, Kentucky
2025-05-28
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Alabama, California, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Iowa
2025-05-22
Recruiting
Minima Stent System Post- Approval Study (PAS)
NCT06828770Pulmonary Artery Stenosis, Aortic Coarctation
Renata Medical
Observational
100
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-05-21
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
4,200
California, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana
2025-05-20
Active, closed
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT06970847Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Drug64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Phase 3
220
California, Florida, Illinois, Indiana, Louisiana, Minnesota, Missouri, Nebraska
2025-05-16
Active, closed
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT06993610Hidradenitis Suppurativa (HS)
Zura Bio Inc
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Massachusetts
2025-05-16
Active, closed
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
NCT06859970Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
InterShunt Technologies, Inc.
Not applicable
20
Arkansas, California, Indiana, Ohio, Texas
2025-05-15
Recruiting
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
NCT06783309Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
72
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-05-12
Active, closed
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
NCT06939283Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.
Phase 1/2
100
Arizona, Georgia, Illinois, Indiana, Texas
2025-05-07
Recruiting
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT06952660Cervical Cancer
DrugTivdak
Pfizer
Phase 4
100
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kentucky
2025-05-07
Active, closed
Evaluating Gingivitis and Systemic Biomarkers
NCT06962956Gingivitis
DrugsSodium monofluorophosphate dentifrice·Stannous Fluoride Dentifrice
Procter and Gamble
Phase 1
135
Indiana
2025-04-30
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
DrugsPelacarsen·Inclisiran
Novartis Pharmaceuticals
Phase 3
340
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-04-30
Recruiting
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
NCT06394869Hematuria - Cause Not Known
Pacific Edge Limited
Not applicable
1,000
Alabama, California, Florida, Indiana, Louisiana, Maryland, New Jersey, New York
2025-04-29
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
905
California, Colorado, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa
2025-04-25
Recruiting
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1/2
146
Colorado, Connecticut, Indiana, Tennessee, Texas
2025-04-25
Recruiting
Evaluating Therapeutic Electrical Stimulation to Improve Nerve Healing After Surgical Repair of Digital Nerve Injuries
NCT06867185Digital Nerve Injury, Nerve Injury, Nerve Reconstruction, Nerve Trauma
Checkpoint Surgical Inc.
Not applicable
60
Indiana, Missouri, Ohio, Washington
2025-04-24
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770Severe Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
288
California, Connecticut, Illinois, Indiana, Kansas, Michigan, Missouri, Nebraska
2025-04-24
Active, closed
Pivotal Study of Voro Urologic Scaffold
NCT06873581Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Levee Medical, Inc.
Phase 3
266
Arizona, California, Florida, Illinois, Indiana, Maryland, Mississippi, New York
2025-04-18
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa
2025-04-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
770
Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Louisiana
2025-04-09
Active, closed
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
710
California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland, Michigan
2025-04-09
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maine
2025-04-04
Recruiting
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
NCT06615050Graft-versus-host Disease (GVHD)
DrugsMycophenolate Mofetil·Tacrolimus·Ruxolitinib·Methotrexate
Incyte Corporation
Phase 3
572
California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan, Missouri
2025-04-02
Recruiting
A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery
NCT06664775Hemorrhage
Corza Medical GmbH
Phase 3
116
California, Colorado, District of Columbia, Illinois, Indiana, Kentucky, Missouri, North Carolina
2025-04-02
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961Atopic Dermatitis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, New York
2025-04-01
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 3
674
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-04-01
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475Type 2 Diabetes
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
Recruiting
The Pivotal Study of RapidPulseTM Aspiration System
NCT06029491Acute Ischemic Stroke
RapidPulse, Inc
Not applicable
170
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Missouri
2025-03-27
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
DrugTozorakimab
AstraZeneca
Phase 2
540
California, Delaware, Florida, Idaho, Indiana, Iowa, Kansas, Kentucky
2025-03-26
Active, closed
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
NCT06857955Hypertension
DrugQCZ484
Novartis Pharmaceuticals
Phase 2
396
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-26
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
NCT06826196Alopecia Areata (AA)
Aldena Therapeutics
Phase 1/2
24
California, Indiana, Massachusetts, Washington
2025-03-24
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
NCT06611163Moderate to Severe Genital Psoriasis
DrugTildrakizumab
Sun Pharmaceutical Industries Limited
Phase 3
206
California, Colorado, Florida, Georgia, Indiana, Michigan, Nebraska, New York
2025-03-21
Active, closed
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
NCT06773962Parkinson's Disease (PD)
TrueBinding, Inc.
Phase 2
62
California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan, New York
2025-03-20
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts
2025-03-19
Recruiting
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942Psoriasis, Overweight or Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-18
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
NCT06915363Knee Pain Chronic, Knee Osteoarthritis, Cartilage Damage, Cartilage Defects of the Knee
BioPoly LLC
Not applicable
152
Indiana, Minnesota, Missouri
2025-03-17
Active, closed
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
DrugMaridebart cafraglutide
Amgen
Phase 3
1,105
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-17
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551Juvenile Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
60
California, Illinois, Indiana, New York, Ohio, Texas
2025-03-13
Active, closed
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
NCT06869785Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
Phase 3
196
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-03-13
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Arizona, California, Florida, Georgia, Idaho, Indiana, Michigan, Missouri
2025-03-11
Active, closed
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264Androgenetic Alopecia, AGA, Male Pattern Baldness
DrugVDPHL01
Veradermics, Inc.
Phase 3
480
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-03-11
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma, c-MET
DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin
AbbVie
Phase 1/2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Massachusetts
2025-03-06
Active, closed
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026Psoriatic Arthritis, Overweight or Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-03-06
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 3
300
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-05
Recruiting
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044Major Depressive Disorder (MDD)
Vanda Pharmaceuticals
Phase 3
500
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-03-03
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
600
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana
2025-02-28
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
DrugAAA817
Novartis Pharmaceuticals
Phase 2/3
443
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
780
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
171
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-02-27
Recruiting
A Study of HS-20110 in Participants With Advanced Solid Tumors
NCT06892379Solid Tumors
DrugHS-20110
Hansoh BioMedical R&D Company
Phase 1
475
Florida, Indiana, North Carolina, Texas, Virginia
2025-02-26
Recruiting
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
NCT07558668Moderate to Severe Atopic Dermatitis
Sitryx Therapeutics Ltd
Phase 1
149
Arkansas, California, Indiana, Ohio, Pennsylvania, Utah
2025-02-26
Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
NCT06778447Degenerative Disc Disease, Disc Degeneration, Lumbar Discogenic Pain
VIVEX Biologics, Inc.
Not applicable
325
California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky, Louisiana
2025-02-17
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505Chronic Migraine
DrugAtogepant
AbbVie
Phase 3
420
Alabama, Arkansas, California, Florida, Indiana, Michigan, Mississippi, Nebraska
2025-02-13
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
231
California, Florida, Georgia, Idaho, Illinois, Indiana, Missouri, New York
2025-02-12
Recruiting
IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers
NCT06616844Wound Heal, Ulcer
ConvaTec Inc.
Not applicable
235
California, Florida, Indiana, Maryland, Massachusetts, New York, North Carolina, Pennsylvania
2025-02-12
Recruiting
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
NCT06533098Thrombocytopenia, Neonatal Alloimmune
DrugsImmunoglobulins·Nipocalimab·IVIG·Prednisone
Janssen Research & Development, LLC
Phase 3
50
Alabama, California, Colorado, Illinois, Indiana, Iowa, New York, North Carolina
2025-02-10
Recruiting
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
NCT06541847Neurofibromatosis Type 1
Healx Limited
Phase 2
25
Alabama, California, Colorado, District of Columbia, Illinois, Indiana, Maryland, Missouri
2025-02-10
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Pathos AI, Inc.
Phase 1/2
120
California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-02-07
Recruiting
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Phase 1/2
108
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2025-02-06
Recruiting
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368Aortic Stenosis
Medtronic Cardiovascular
Observational
225
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana
2025-02-06
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-02-05
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin
BioNTech SE
Phase 3
621
Arizona, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana
2025-02-03
Recruiting
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527Rotator Cuff Tears of the Shoulder
Anika Therapeutics, Inc.
Not applicable
150
Arizona, California, Florida, Georgia, Indiana, Maryland, New Jersey, South Carolina
2025-02-01
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
588
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-01-31
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience
Merck Sharp & Dohme LLC
Phase 3
1,046
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-01-27
Recruiting
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 1/2
258
Florida, Indiana, Kansas, Massachusetts, Missouri, Washington
2025-01-23
Recruiting
A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing
NCT06625385Wound
Solventum US LLC
Not applicable
90
Indiana, Missouri, Pennsylvania
2025-01-20
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847Primary Sjogrens Disease
DrugEfgartigimod PH20
argenx
Phase 3
631
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-15
Recruiting
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543Colorectal Cancer
DrugFruquintinib
Takeda
Phase 4
78
Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Indiana
2025-01-14
Recruiting
PerQdisc Traditional Feasibility Trial.
NCT06860867Discogenic Low Back Pain
Spinal Stabilization Technologies
Not applicable
5
Arizona, Idaho, Indiana, Louisiana, Oklahoma
2025-01-10
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
NCT06740630Chickenpox
DrugsHepatitis A vaccine·MMR vaccine·PCV (pneumococcal conjugate vaccine) 13·PCV 20
GlaxoSmithKline
Phase 3
1,840
Alabama, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-10
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky
2025-01-08
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin
BioNTech SE
Phase 2/3
1,580
Alabama, Alaska, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-01-07
Recruiting
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410Cutaneous Squamous Cell Carcinoma (CSCC)
DrugCemiplimab
Regeneron Pharmaceuticals
Phase 3
369
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky
2025-01-02
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910Crohn's Disease
DrugsVedolizumab·Upadacitinib
Takeda
Phase 3
396
California, Colorado, Florida, Indiana, Kentucky, New York, South Carolina, South Dakota
2025-01-02
By invitation
The ION Facet Screw System Ambispective Evaluation
NCT06720948Intra-facet ION 3D Facet Screw System
SurGenTec LLC
Observational
50
Indiana, Oklahoma, Texas
2025-01-01
Active, closed
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
NCT06768671Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
35
Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Kentucky
2024-12-30
Active, closed
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190Multifocal Motor Neuropathy (MMN), MMN
DrugsEmpasiprubart·Immunoglobulin·IVIG
argenx
Phase 3
154
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-12-18
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
240
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2024-12-17
Active, closed
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
NCT06777433Brain Metastases From Solid Tumors
Radiopharm Theranostics, Ltd
Phase 2
30
Illinois, Indiana, Michigan
2024-12-13
Active, closed
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma
DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine
Arcus Biosciences, Inc.
Phase 3
610
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-12-13
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Abbott Medical Devices
Not applicable
850
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-12-13
Recruiting
Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation
NCT05945329Capsular Contracture Associated With Breast Implant, Capsular Contracture Grade III, Capsular Contracture Grade IV
C. R. Bard
Not applicable
250
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2024-12-12
Active, closed
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
350
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-12-11
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Alabama, California, Georgia, Indiana, Kentucky, Maryland, Michigan, Minnesota
2024-12-11
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide
Amgen
Phase 3
707
Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan
2024-12-09
Recruiting
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
NCT06706674Irritability Associated With Autism Spectrum Disorder
DrugLumateperone
Intra-Cellular Therapies, Inc.
Phase 3
160
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2024-12-06
Active, closed
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
NCT06706622Multiple System Atrophy
DrugAmlenetug
H. Lundbeck A/S
Phase 3
401
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Indiana, Maryland
2024-12-03
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Arizona, California, District of Columbia, Illinois, Indiana, Kansas, Maryland, Massachusetts
2024-12-03
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698Chronic Kidney Disease
DrugSemaglutide
Novo Nordisk A/S
Phase 2
465
California, Colorado, Florida, Illinois, Indiana, Michigan, Missouri, New York
2024-12-02
Active, closed
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742Wet Age Related Macular Degeneration, wAMD
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2024-11-27
Active, closed
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918Neovascular Age-related Macular Degeneration
DrugsOtx-Tki·Aflibercept
Ocular Therapeutix, Inc.
Phase 3
825
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-27
Active, closed
Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT06498960Normal Pressure Hydrocephalus
CereVasc Inc
Not applicable
230
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Massachusetts
2024-11-26
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsDocetaxel·Pembrolizumab
Genmab
Phase 3
191
Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky
2024-11-25
Active, closed
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
NCT06668805Noonan Syndrome
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
30
California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-11-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-11-21
Recruiting
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach
NCT06653387Carotid Artery Diseases
InspireMD
Not applicable
50
California, Indiana, Minnesota, Missouri, Montana, New York, Ohio
2024-11-20
Active, closed
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
Fluidx Medical Technology, Inc.
Not applicable
114
California, Colorado, Illinois, Indiana, Minnesota, Missouri, New York, North Carolina
2024-11-18
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
125
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-18
Recruiting
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06752681Advanced or Metastatic Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 1
300
Connecticut, Florida, Indiana, Michigan, New York, Oklahoma, Tennessee, Texas
2024-11-18
Recruiting
AvertD Post-Approval Study
NCT07135323Opioid Use Disorder
Prescient Medicine Holdings, Inc.
Observational
4,000
Indiana
2024-11-15
Recruiting
Bone Mineral Density Precision Study
NCT06830811Indicated for EOSedge Imaging
Alphatec Spine, Inc.
Not applicable
30
Indiana
2024-11-13
Recruiting
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)
NCT06462729Degenerative Disc Disease, Lumbar Disc Disease, Spine Disease, Lumbar Spine Degeneration
Locate Bio Pty Ltd
Phase 1/2
40
Indiana, North Carolina, Tennessee
2024-11-12
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Iowa
2024-11-12
Active, closed
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
NCT06614192Metastatic Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
74
California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-11-08
Active, closed
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT06659640Hereditary Hemorrhagic Telangiectasia
DrugALN-6400
Alnylam Pharmaceuticals
Phase 1/2
89
Alabama, California, Florida, Indiana, Massachusetts, Minnesota, Missouri, North Carolina
2024-11-07
Recruiting
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
NCT05582993Von Willebrand Disease (VWD)
DrugsAdvate·Vonicog Alfa
Takeda
Phase 3
24
Alabama, Florida, Illinois, Indiana, Iowa, Michigan, Minnesota, Nevada
2024-11-06
Not yet open
A Clinical Study to Evaluate the Ultrasonic Detection of a Novel Nasogastric Tube in the Human Body.
NCT06497088Nasogastric Tube Placement
Nasotrak Medical Pte Ltd
Not applicable
90
Indiana, New York
2024-11-01
Active, closed
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
NCT06602232Alopecia Areata, Vitiligo
DrugDibotatug
Dren Bio
Phase 1
81
California, Florida, Georgia, Idaho, Indiana, Massachusetts, Michigan, Pennsylvania
2024-10-30
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Georgia, Indiana, Ohio, Texas, Utah
2024-10-29
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas
2024-10-29
Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031Cardiovascular Diseases, Heart Diseases, Heart Failure
BrioHealth Solutions, Inc.
Not applicable
780
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2024-10-28
Recruiting
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
NCT06049680Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
DrugSmoflipid
Fresenius Kabi
Phase 4
100
Georgia, Illinois, Indiana, Ohio, Pennsylvania
2024-10-28
Active, closed
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706Glioma
DrugsAbemaciclib·Temozolomide
Eli Lilly and Company
Phase 2
45
California, Indiana, Maryland, Michigan, Minnesota, Rhode Island, Texas
2024-10-25
Active, closed
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
NCT06321601Vasculitis
DrugAvacopan
Amgen
Phase 3
19
Georgia, Indiana, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Texas
2024-10-22
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422Carcinoma, Non-Small-Cell Lung
DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
680
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2024-10-21
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Active, closed
Esprit BTK Post-Approval Study
NCT06656364Chronic Limb-Threatening Ischemia
Abbott Medical Devices
Not applicable
200
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-10-21
Recruiting
The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism
NCT06433011Pulmonary Embolism
Thrombolex, Inc.
Not applicable
500
Arizona, Florida, Georgia, Illinois, Indiana, Massachusetts, Mississippi, New Hampshire
2024-10-17
Recruiting
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
NCT06538558Opioid Use Disorder
Proniras Corporation
Phase 1
40
Indiana
2024-10-16
Recruiting
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms
DrugsFolfiri·Folfox·Bevacizumab
Janssen Research & Development, LLC
Phase 1
260
Arizona, Colorado, Florida, Indiana, Michigan, Washington
2024-10-15
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2024-10-14
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432Solid Tumours
DrugZongertinib
Boehringer Ingelheim
Phase 2
588
Alaska, Arizona, California, Connecticut, Florida, Illinois, Indiana, Maryland
2024-10-11
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952Prurigo Nodularis
DrugPovorcitinib
Incyte Corporation
Phase 3
349
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Michigan
2024-10-10
Recruiting
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
NCT06525636X-linked Hypophosphatemia
Kyowa Kirin Co., Ltd.
Phase 1/2
39
California, Connecticut, Indiana, Minnesota, Tennessee
2024-10-09
Recruiting
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
DrugCapecitabine
Processa Pharmaceuticals
Phase 2
90
Arizona, California, Florida, Indiana, Maryland, New Jersey, New York, Ohio
2024-10-02
Recruiting
Post-Market Clinical Investigation of the IotaSOFT Insertion System
NCT06664697Hearing Loss, Cochlear, Cochlear Implantation, Hearing Loss, Sensorineural
iotaMotion, Inc.
Observational
50
Indiana, Iowa, Oregon
2024-10-01
Recruiting
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT06551142Neoplasms
DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab
GlaxoSmithKline
Phase 1
845
California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina
2024-09-30
Recruiting
Registry for Stage 2 Type 1 Diabetes
NCT06481904Type 1 Diabetes
DrugTzield
Sanofi
Observational
200
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-09-27
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
DrugGSK4532990
GlaxoSmithKline
Phase 2
393
Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2024-09-27
Recruiting
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
NCT06539507Netherton Syndrome
BioCryst Pharmaceuticals
Phase 1
78
California, Connecticut, Illinois, Indiana
2024-09-26
Recruiting
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
NCT06564974Duchenne Muscular Dystrophy
DrugVamorolone
Catalyst Pharmaceuticals, Inc.
Observational
250
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2024-09-25
Recruiting
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
NCT06462235Gram-negative Bacterial Infection
Pfizer
Phase 2
48
California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas
2024-09-25
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
DrugSotagliflozin
Lexicon Pharmaceuticals
Phase 3
500
Arizona, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts
2024-09-24
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Arizona, California, Florida, Georgia, Illinois, Indiana, Maine, Maryland
2024-09-19
Active, closed
Safety and Effectiveness of Cochlear Implantation in an Expanded Adult Population
NCT06293482Hearing Loss, Sensorineural, Hearing Loss, Bilateral
Cochlear
Not applicable
50
Arizona, California, Florida, Indiana, Missouri, New York, Ohio, Pennsylvania
2024-09-17
Active, closed
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 4
500
California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Louisiana
2024-09-17
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
400
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-09-17
Recruiting
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
DrugAtezolizumab
KaliVir Immunotherapeutics
Phase 1
60
California, Florida, Indiana, Pennsylvania, Texas
2024-09-16
Recruiting
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743High-Risk Non-Muscle-Invasive Bladder Cancer
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 2
325
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-09-16
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Cetuximab·Irinotecan·Adrucil
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Non-cystic Fibrosis Bronchiectasis
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
284
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Iowa
2024-09-11
Recruiting
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
NCT06379789Hemophilia B
Regeneron Pharmaceuticals
Phase 1/2
130
California, Colorado, Connecticut, Florida, Indiana, Louisiana, Michigan, Ohio
2024-09-11
Recruiting
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
NCT06423430Treatment Resistant Depression
Abbott Medical Devices
Not applicable
100
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Minnesota
2024-09-11
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland
2024-09-11
Recruiting
Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures
NCT06477172Post Procedural Erythema
Acorn Biolabs Inc.
Observational
500
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Michigan
2024-09-09
Recruiting
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
NCT06445608Coronary Artery Disease
Kardion Inc
Not applicable
310
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Indiana, Massachusetts
2024-09-03
Active, closed
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
NCT06484114Obesity, Weight Change Trajectory, Weight Change, Body
Fractyl Health Inc.
Not applicable
315
Arizona, California, Florida, Indiana, Michigan, New Hampshire, New York, Pennsylvania
2024-09-01
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
DrugsS095029·Keytruda·Pembrolizumab
Servier Bio-Innovation LLC
Phase 1/2
48
Florida, Indiana, Texas
2024-08-31
Recruiting
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
NCT06610201Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Observational
200
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2024-08-30
Active, closed
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
99
California, District of Columbia, Georgia, Indiana, Minnesota, New Jersey, New York, South Carolina
2024-08-29
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin
Gilead Sciences
Phase 3
640
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-28
Recruiting
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis
DrugsKYV-101·Fludarabine·Cyclophosphamide
Kyverna Therapeutics
Phase 2/3
66
California, Florida, Indiana, Missouri, Oregon, Pennsylvania, Texas, Utah
2024-08-28
Active, closed
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368Wet Age-related Macular Degeneration
DrugsTabirafusp tedromer·Eylea·Aflibercept
Kodiak Sciences Inc
Phase 3
675
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-23
Active, closed
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498Multiple Myeloma
DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib
Kite, A Gilead Company
Phase 3
452
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-08-23
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
DrugsUpadacitinib·Dupilumab
AbbVie
Phase 3
675
Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Kentucky
2024-08-19
Active, closed
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
NCT06601166Type 2 Diabetes
DexCom, Inc.
Not applicable
283
Colorado, Florida, Georgia, Indiana, Minnesota, Missouri, New York, North Carolina
2024-08-15
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Lenalidomide·Rituximab·Oxaliplatin
Genmab
Phase 3
379
California, Colorado, Georgia, Illinois, Indiana, Kansas, Kentucky, Maryland
2024-08-13
Active, closed
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
NCT06524375Chronic Lymphocytic Leukemia
DrugVenetoclax
Genentech, Inc.
Phase 2
118
Arkansas, Colorado, Florida, Indiana, Iowa, Maryland, Massachusetts, Nebraska
2024-08-09
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
110
California, Colorado, Connecticut, Illinois, Indiana, Massachusetts, Minnesota, New York
2024-08-08
Recruiting
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019Chronic Lymphocytic Leukemia
DrugsAcalabrutinib·Obinutuzumab·Venetoclax
AbbVie
Phase 3
170
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa
2024-08-05
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
DrugsEnlicitide Decanoate·Enlicitide
Merck Sharp & Dohme LLC
Phase 3
3,000
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-08-05
Active, closed
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
DrugsPumitamig·Topotecan·Etoposide·Paclitaxel
BioNTech SE
Phase 2
110
Alaska, California, Florida, Illinois, Indiana, Kentucky, Minnesota, Missouri
2024-08-05
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsSaruparib·Camizestrant·Exemestane·Anastrozole
AstraZeneca
Phase 3
788
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Maryland
2024-08-01
Active, closed
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892Respiratory Syncytial Virus Infections
DrugRSVPreF3 OA vaccine
GlaxoSmithKline
Phase 3
10,212
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2024-08-01
Recruiting
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NCT06216301Metastatic Non-small Cell Lung Cancer
DrugPembrolizumab
NovoCure GmbH
Phase 3
734
Alabama, Arizona, California, Florida, Illinois, Indiana, Kansas, Missouri
2024-07-31
Active, closed
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
NCT06565650Dry Eye
Bausch & Lomb Incorporated
Phase 4
216
California, Florida, Georgia, Indiana, Missouri, North Carolina, Tennessee
2024-07-31
Recruiting
Investigations of Reproductive Cancers in Women
NCT06527157Uterine Cancer
PinkDx, Inc.
Observational
4,500
Alabama, California, Florida, Illinois, Indiana, Minnesota, Missouri, New York
2024-07-30
Active, closed
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
NCT06347016Severe Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
311
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Maryland
2024-07-23
Active, closed
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807Tricuspid Regurgitation, Tricuspid Valve Disease
P+F Products + Features USA Inc.
Not applicable
50
Arizona, California, Florida, Illinois, Indiana, Louisiana, Massachusetts, Minnesota
2024-07-23
Active, closed
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
DrugRYZ101
RayzeBio, Inc.
Phase 1/2
16
Arizona, California, Colorado, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-07-19
Active, closed
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
DrugsEnfortumab Vedotin·Sacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
38
California, Illinois, Indiana, Massachusetts, Missouri, New York, Ohio, Utah
2024-07-17
Rows per page Showing 1–500 of 1124
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/indiana

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,124 of those studies with a site in Indiana.

How many clinical trials are recruiting in Indiana?

558 of the 1,124 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 19 have not yet opened recruitment, 522 are active but closed to new participants, and 25 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Indiana), 1,124 studies
PhaseStudiesRecruitingShare
Phase 342218537.5%
Phase 21929217.1%
Not applicable1557113.8%
Observational1327111.7%
Phase 180537.1%
Phase 1/277466.9%
Phase 2/336243.2%
Phase 430162.7%

Most active sponsors

Lead sponsors with the most studies (Indiana)
Lead sponsorStudiesRecruiting
Eli Lilly and Company4928
AbbVie4121
AstraZeneca4115
Janssen Research & Development, LLC3917
Merck Sharp & Dohme LLC3210
Novartis Pharmaceuticals3112
Pfizer2517
Novo Nordisk A/S2310
Hoffmann-La Roche186
Regeneron Pharmaceuticals1814
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.